The company identifies bioactive molecules secreted by the gut microbiome that play a central role in regulating human physiology and the immune system. Enterome's pharmaceuticals and diagnostics tests treat metabolic and bowel diseases by targeting abnormalities in the bacterial composition of the human intestine. They are currently developing breakthrough immunomodulatory drugs for cancer and inflammatory diseases, including two pipelines of clinical and pre-clinical candidates: OncoMimics™ and EndoMimics™. Additionally, Enterome's clinical candidate sibofimloc is advancing through a Phase 2 clinical trial in post-operative Crohn's disease, which has been partnered with Takeda globally.